David Powley

Vice President, Reproductive Medicine and Maternal Health Business Unit

David Powley is responsible for the Ferring Reproductive Medicine and Maternal Health Business Unit.

David has more than 25 years of pharmaceutical industry experience in U.S. and global markets across a wide range of therapeutic areas. He joined Ferring in 2015 as leader of the Orthopaedics Business Unit. He assumed leadership of the Reproductive Medicine and Maternal Health Business Unit in 2018. Prior to Ferring, he held roles of increasing responsibility in sales and marketing at Sanofi. David began his career at Abbott and Pharmacia, now part of Pfizer.

David holds an MBA degree from Villanova University and a Bachelor of Arts degree in Political Science & History from Alfred University.

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2100028